Publication NumberUS 20190060434
Assignees
  • TAIGA BIOTECHNOLOGIES, INC.
StatusPatent Application
Application Number16/184086
AvailabilityUnknown
Filing Date2018-11-08
Publication Date2019-02-28

Abstract

Provided herein are methods and compositions for the treatment of melanoma using anti-tumor immune cells treated with a PTD-MYC fusion protein (e.g., an HIV TAT-MYC fusion protein).

Claims

  • 1. A composition comprising: (a) a MYC fusion peptide, comprising (i) a protein transduction domain; (ii) a MYC polypeptide sequence; and (b) one or more primary immune cells isolated from a donor subject that has a melanoma tumor, wherein the one or more primary immune cells are reactive against a melanoma-specific antigen.
  • 2. The composition of claim 1, wherein the protein transduction domain sequence is a TAT protein transduction domain sequence.
  • 3. The composition of claim 1, wherein the MYC fusion peptide comprises SEQ ID NO: 1.
  • 4. The composition of claim 1, wherein the one or more immune cells comprises a T cell, a B cell, an NK cell, or any combination thereof.
  • 5. The composition of claim 1, wherein the one or more immune cells comprises a tumor-infiltrating lymphocyte, T-cell receptor modified lymphocyte, or a chimeric antigen receptor modified lymphocyte.
  • 6. The composition of claim 5, wherein the tumor-infiltrating lymphocyte has a CD8+CD25+ signature or a CD4+CD25+ signature.
  • 7.-20. (canceled)